Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSI-953 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| GSI-953 | DRUG | - |
| Placebo | OTHER | - |
Inclusion Criteria: * For Healthy Young Subjects: Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs and 12 lead ECGs. * For AD patients: Patients must be generally healthy with the exception of Alzheimer Di...
Top 20 of 30 competitors
GSI-953 is an investigational small molecule being developed by Pfizer, Inc. for Alzheimer disease. It is a neurology asset that has been studied in a Phase 1 clinical trial. GSI-953 is not approved and remains in early clinical development.
GSI-953 is being studied for the treatment of Alzheimer disease. The only clinical trial of GSI-953 listed to date enrolled participants with Alzheimer disease along with healthy volunteers. It is an investigational therapy and has not been approved for any use.
GSI-953 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 study of GSI-953 conducted in the United States.
GSI-953 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. GSI-953 is investigational and has not been approved by the FDA for Alzheimer disease or any other indication.
GSI-953 has been evaluated in one completed Phase 1 trial, NCT00479219, titled Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients. That trial enrolled 17 participants in the United States, was randomized, double blind, and placebo controlled, and included healthy volunteers.
The completed Phase 1 trial of GSI-953, NCT00479219, enrolled 17 participants. It was a randomized, double blind, placebo controlled study that included both healthy young volunteers and patients with Alzheimer disease, and it was conducted in the United States.